RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. - Publication

Publication

RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial.

Journal Paper/Review - Sep 19, 2023

Link Theresa, Blohmer Jens-Uwe, Schmitt Wolfgang Daniel, Kuhlmann Jan Dominik, Just Marianne, Untch Michael, Stötzer Oliver, Fasching Peter Andreas, Thill Marc, Reinisch Mattea, Schneeweiss Andreas, Wimberger Pauline, Seiler Sabine, Huober Jens, Jackisch Christian, Rhiem Kerstin, Hanusch Claus, Sinn Bruno Valentin, Nekljudova Valentina, Loibl Sibylle, Denkert Carsten

Citation

Link T, Blohmer J, Schmitt W, Kuhlmann J, Just M, Untch M, Stötzer O, Fasching P, Thill M, Reinisch M, Schneeweiss A, Wimberger P, Seiler S, Huober J, Jackisch C, Rhiem K, Hanusch C, Sinn B, Nekljudova V, Loibl S, Denkert C. RANK expression as an independent predictor for response to neoadjuvant chemotherapy in luminal-like breast cancer - a translational insight from the GeparX trial. Clin Cancer Res 2023

Type

Journal Paper/Review (English)

Journal

Clin Cancer Res 2023

Publication Date

Sep 19, 2023

Issn Electronic

1557-3265

Brief description/objective

The GeparX study investigated whether denosumab as add-on treatment to nab-paclitaxel-based neoadjuvant chemotherapy (NACT) with two different schedules (125mg/m² weekly vs. day 1, 8 q22) may increase pathological complete response (pCR) rate. The addition of denosumab to NACT did not improve pCR rates as recently published. In this study, we investigated whether RANK expression, as part of the denosumab target pathway, a) may retrospectively identify a subgroup of patients with additional clinical benefit of denosumab or b) may predict response to nab-paclitaxel NACT.